Why the study?
Cardiotoxic effects of anticancer and antiretroviral therapies undermine therapeutic efficacy and survival, requiring improved awareness, early detection, and management of drug-induced cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Routine monitoring of left ventricular function is critical in patients receiving cardiotoxic anticancer and antiretroviral therapies to prevent irreversible heart failure.
Drug-induced cardiomyopathy (CM) is a potentially reversible form of acquired CM and a common consequence of exposure to numerous medically prescribed drugs. It is particularly a common serious adverse side effect of anticancer and antiretroviral therapies. The two drugs may have significantly improved longevity in cancer and HIV-infected patients respectively but their cardiotoxic effects threaten to undermine their therapeutic efficacy and reduce survival in affected patients. Hospitalization due to drug-induced CM also places a considerable burden on the healthcare system in terms of reduced drug efficacy and patient management. Early detection is clinically important for improve efficacy in the management of drug-induced CM as well as the prevention of the progression into heart failure. Thus, prescribers should be fully aware of drugs with the potential to cause CM and the clinical value of monitoring the cardiotoxic effects of these drugs. Thus, the present paper provides a systematic review of literature and meta-analysis of diagnosis and management methods. The aim is to broaden the understanding of the major causative drugs, pathophysiology, diagnosis and management of drug-induced CM.
No takes yet. Share an insight, caveat, or question.
Aref Albakri (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: